Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICI), alone or in combination with other agents, are now standard of care for a range of tumour types, including breast cancer. Radiological assessment of baseline tumour burden has been associated with prognosis in a variety of tumour types treated with immunotherapeutic agents. Whether baseline tumour burden is prognostic in breast cancer treated with ICI is unknown.

Methods

A retrospective review of patients from a single institution with advanced breast cancer treated with ICI was performed. The sum of baseline target lesion measurements (baseline tumour size [BTS]) and all lesions (total tumour burden [TTB]) were determined in accordance with RECIST version 1.1 and correlated with clinical outcomes.

Results

82 patients wer

SUBMITTER: Dixon-Douglas J 

PROVIDER: S-EPMC12514349 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature